ABSORB STEMI: the TROFI II Study

NACompletedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

January 6, 2014

Primary Completion Date

April 13, 2015

Study Completion Date

September 21, 2017

Conditions
Acute ST Segment Elevation Myocardial Infarction
Interventions
DEVICE

Percutaneous Coronary Intervention

"Implanting a device (Xience Xpedition stent or Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS) to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point."

Trial Locations (8)

Unknown

Research centre Aarhus, DK003, Aarhus

Research centre Odense, DK002, Odense

Research centre Leeuwarden, NL002, Leeuwarden

Research centre Nieuwegein, NL014, Nieuwegein

Research centre Barcelona, ES001, Barcelona

Research centre Barcelona, ES003, Barcelona

Research centre Vigo, ES004, Vigo

Research centre Bern, CH006, Bern

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott Medical Devices

INDUSTRY

collaborator

Terumo Europe N.V.

INDUSTRY

lead

ECRI bv

INDUSTRY

NCT01986803 - ABSORB STEMI: the TROFI II Study | Biotech Hunter | Biotech Hunter